SPREAD-NET: PRactices Enabling Adapting and Disseminating in the safety NET

描述(由申请人提供)：国家的“安全网”社区卫生中心(CHC)可以从实施被证明在改善其他环境下的卫生保健过程和结果方面有效的干预措施中受益匪浅。然而，缺乏对支持在CHC实施循证干预措施的最有效战略的了解，是及时传播临床创新的主要障碍。我们的长期目标是学习如何最好地将循证干预传播到全国范围内的社区卫生保健中心。为了实现这一目标，我们建议比较不同的支持策略在帮助不同的CHC可持续地实施干预措施方面的有效性，这些干预措施被证明可以降低患者的心血管疾病(CVD)事件风险。Kaiser Permanente制定并实施了‘All Initiative’(也就是All)，这是一种临床层面的干预措施，旨在根据循证指南提高成年糖尿病(DM)或心血管疾病患者服用心脏保护药物(他汀类药物和血管紧张素转换酶抑制剂)的比率。在Kaiser Permanente的综合护理环境中，所有这些都被证明是非常有效的，我们的团队在大量实施支持的帮助下，证明了将其应用于11家CHC成功实施的可行性。这项研究的下一步是确定在更多的社区保健中心有效实施和维持这一干预措施所需的支持数量和类型。为此，我们将进行一项试验，将30个中心随机分组，以在实施ALL时获得低、中、高强度的支持。我们将与OCHIN的CHC成员一起进行这项工作，OCHIN是一个社区卫生信息技术网络，托管着全国最大的CHC电子健康记录(EHR)平台之一；研究CHC共享一个单一的、链接的EHR。在实践变革模式和RE-AIM框架的指导下，我们将使用混合方法：目标1：比较低、中、高强度策略支持CHC实施ALL的有效性，并评估临床患者使用(I)指南适当的心脏保护处方，以及(Ii)控制的血压和低密度脂蛋白，与不同策略支持的实施相关的比率的变化；目标2：评估这些策略在支持3年以上干预可持续性方面的有效性；以及目标3：确定在不同支持水平下与干预成功相关的临床特征。我们的团队包括CHC临床医生，以及传播和实施(D&I)、卫生经济学和卫生服务研究混合方法方面的专家。我们的研究旨在为未来实施ALL以及其他已知的改善CHC糖尿病/心血管疾病患者预后的干预措施提供信息。我们的结果还可以通过比较在CHC和其他门诊环境中支持临床创新实施的实用、可推广的方法，对D&I科学产生很大影响。

DESCRIPTION (provided by applicant): The nation's 'safety net' community health centers (CHCs) could benefit greatly from implementing interventions shown to be effective at improving health care processes and outcomes in other settings. However, a lack of knowledge about the most effective strategies for supporting implementation of evidence-based interventions in CHCs presents a major barrier to the timely dissemination of clinical innovations. Our long-term goal is to learn how best to disseminate evidence-based interventions into CHCs nationwide. Working towards that goal, we propose to compare the effectiveness of different 'support strategies' at helping diverse CHCs sustainably implement an intervention shown to reduce patients' cardiovascular disease (CVD) event risk. Kaiser Permanente developed and implemented the 'ALL Initiative' (a.k.a. 'ALL'), a clinic-level intervention designed to increase rates of adult patients with diabetes mellitus (DM) or CVD who are prescribed cardio-protective medications (statins and ACE-Inhibitors) according to evidence-based guidelines. After ALL was shown to be highly effective in Kaiser Permanente's integrated care setting, our team demonstrated the feasibility of adapting it for successful implementation in 11 CHCs - with the help of substantial implementation support. The next step in this body of research is to identify the amount and type of support needed to effectively implement and sustain this intervention in a greater number of CHCs. To that end, we will conduct a trial in which 30 CHCs are cluster-randomized to receive low, medium, or high-intensity support in implementing ALL. We will conduct this work with CHC members of OCHIN, a community health information technology network that hosts one of the nation's largest CHC electronic health record (EHR) platforms; study CHCs share a single, linked EHR. Guided by the Practice Change Model and RE-AIM framework, we will use mixed-methods to: Aim 1: Compare how effectively the low, medium, and high-intensity strategies support the CHCs' implementation of ALL, and assess change in rates of clinic patients with (i) guideline-appropriate cardioprotective prescriptions, and (ii) controlled blood pressure and low-density lipoprotein, as associated with implementation supported by the different strategies; Aim 2: Assess the strategies' effectiveness at supporting intervention sustainability over 3 years; and Aim 3: Identify clinic characteristics associated wit success at different levels of support. Our team includes CHC clinicians, and experts in dissemination and implementation (D&I), health economics, and health services research mixed-methods. Our study is designed to inform future implementation of ALL as well as other interventions known to improve outcomes among CHC patients with DM / CVD. Our results could also have high impact on D&I science, by comparing practical, generalizable methods for supporting the implementation of clinical innovations in CHCs and other ambulatory settings.